logo
    Docs
 

Disease Report: Parkinson's Disease


Groups and Companies
Funding
Standard of Care
Unmet Medical Need
Novel Modalities and Combinations
Symptoms Evidence
Symptoms Targets
Pathogenesis Evidence
Pathogenesis Targets
Assays and Models

1. Hypothesis Summary:

The hypothesis posits that the loss of dopaminergic neurons in Parkinson's Disease (PD) leads to functional deficits in supraspinal structures, which in turn results in an imbalance in the endogenous descending modulation of pain. This imbalance may contribute to the development of pathological pain as a significant non-motor symptom in PD.

2. Mechanism and Evidence:

The loss of dopaminergic neurons affects various neurotransmitter systems, leading to altered pain modulation. Dopaminergic pathways are crucial for the integration and modulation of nociceptive signals in supraspinal structures, such as the periaqueductal gray matter and the locus coeruleus. The hypothesis suggests that the degeneration of these neurons disrupts normal pain processing, resulting in heightened pain sensitivity or pathological pain.
  • Evidence: Lei et al. (2024) highlight that deficits in dopaminergic pathways affect non-dopaminergic neurotransmitter systems, contributing to the pathological processing of nociceptive input in PD (PMID: 38569983).

3. Clinical Evidence:

Clinical studies indicate that pain is a prevalent non-motor symptom in PD, often occurring before the onset of motor symptoms. Patients with PD frequently report chronic pain, which is believed to be linked to the loss of dopaminergic neurons and subsequent changes in pain modulation.
  • Evidence: Cattaneo and Jost (2023) discuss the high prevalence of pain in PD and its significant impact on quality of life, emphasizing the need for effective pain management strategies (PMID: 37735139).

4. Genetic Targets and Evidence:

Genetic factors influencing dopaminergic neuron survival and function may play a role in pain modulation. Variants in genes associated with dopamine synthesis and signaling could affect individual susceptibility to pain in PD.
  • Evidence: Research on genetic polymorphisms related to dopamine receptors and their impact on pain perception in PD is still emerging, but studies suggest a potential link between genetic predisposition and pain sensitivity.

5. Protein Targets and Evidence:

Proteins involved in dopaminergic signaling, such as tyrosine hydroxylase (TH), are critical for dopamine synthesis. Alterations in TH activity due to neuroinflammatory processes may contribute to the loss of dopaminergic neurons and subsequent pain modulation deficits.
  • Evidence: Kim et al. (2017) demonstrate that the HMGB1-RAGE axis can influence TH expression, suggesting that neuroinflammatory mediators may impact dopaminergic neuron function and pain modulation (PMID: 28887039).

6. Pathways and Evidence:

The dopaminergic pathway interacts with various other neurotransmitter systems, including serotonergic and noradrenergic pathways, which are also involved in pain modulation. The interplay between these systems may be disrupted in PD, leading to altered pain perception.
  • Evidence: Campos et al. (2019) show that the preservation of noradrenergic and serotonergic systems regulates nociceptive circuitry during PD, indicating that non-dopaminergic pathways are essential for pain modulation (PMID: 31028827).

7. Cellular Targets and Evidence:

Supraspinal structures, including the periaqueductal gray and locus coeruleus, are critical for descending pain modulation. The loss of dopaminergic input to these areas may lead to hyperexcitability and altered pain processing.
  • Evidence: Zhang et al. (2024) found that activation of the pedunculopontine tegmental nucleus can alleviate pain induced by the lesion of midbrain dopaminergic neurons, suggesting that these structures play a role in pain modulation (PMID: 38891832).

8. Tissue Targets and Evidence:

The substantia nigra and other regions affected by dopaminergic neuron loss are involved in pain processing. Changes in these tissues can lead to dysregulation of pain pathways.
  • Evidence: The degeneration of dopaminergic neurons in the substantia nigra is a hallmark of PD and is associated with the development of chronic pain in patients (PMID: 38569983).

9. Additional Context:

The relationship between dopaminergic neuron loss and pain in PD is complex and multifactorial. While the hypothesis is supported by evidence linking dopaminergic dysfunction to altered pain modulation, it is essential to consider the contributions of non-dopaminergic systems and the role of neuroinflammation. Current treatment options for pain in PD, such as dopaminergic medications, may not adequately address the underlying mechanisms of pain, highlighting the need for further research into targeted therapies that consider the multifaceted nature of pain in PD.
In conclusion, while there is substantial evidence supporting the hypothesis that the loss of dopaminergic neurons contributes to pathological pain in PD through functional deficits in supraspinal structures, further research is needed to fully elucidate the mechanisms involved and to develop effective treatment strategies.